Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations

BACKGROUND: Due to the decreasing prevalence of IDH1 mutations in older patients, the 2016 World Health Organization (WHO) classification of brain tumors proposed not to perform sequencing for isocitrate dehydrogenase (IDH) in glioblastoma patients ≥55 years old. We present a cost-effectiveness anal...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: DeWitt, John C, Jordan, Justin T, Frosch, Matthew P, Samore, Wesley R, Iafrate, A John, Louis, David N, Lennerz, Jochen K
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2017
Fag:
Clinical Investigations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5716163/
https://ncbi.nlm.nih.gov/pubmed/29016871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox120
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker